Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic

Allarity Therapeutics, Inc.

IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.
Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.
Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.
Applications pending in US, Canada, Japan, China, and India.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.